News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 25

    Sep

    20

  • KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

  • 10

    Sep

    20

  • KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

  • 02

    Sep

    20

  • KemPharm to Present at Upcoming September Investor Conferences

  • 14

    Aug

    20

  • KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

  • 12

    Aug

    20

  • KemPharm Reports Second Quarter 2020 Financial Results

  • 04

    Aug

    20

  • KemPharm to Report Second Quarter 2020 Financial Results

  • 28

    Jul

    20

  • KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484

  • 18

    Jun

    20

  • KemPharm Issues Letter to Shareholders

  • 19

    May

    20

  • KemPharm Receives Day-74 Letter for KP415 NDA

  • 12

    May

    20

  • KemPharm Reports First Quarter 2020 Financial Results

  • 06

    May

    20

  • KemPharm to Report First Quarter 2020 Financial Results

  • 04

    May

    20

  • NDA Filing for Potential New ADHD Treatment, KP415, Accepted by FDA; KemPharm Eligible to Receive $5 Million Milestone Payment from Gurnet Point Capital